1. Home
  2. ADBE vs VRTX Comparison

ADBE vs VRTX Comparison

Compare ADBE & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adobe Inc.

ADBE

Adobe Inc.

HOLD

Current Price

$334.24

Market Cap

134.0B

Sector

Technology

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$451.62

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADBE
VRTX
Founded
1982
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
134.0B
115.7B
IPO Year
1986
1991

Fundamental Metrics

Financial Performance
Metric
ADBE
VRTX
Price
$334.24
$451.62
Analyst Decision
Buy
Buy
Analyst Count
23
24
Target Price
$428.95
$497.77
AVG Volume (30 Days)
4.4M
1.3M
Earning Date
12-10-2025
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
35.11
N/A
EPS
16.70
14.22
Revenue
$23,769,000,000.00
$11,723,300,000.00
Revenue This Year
$11.70
$11.01
Revenue Next Year
$9.21
$8.74
P/E Ratio
$20.96
$31.88
Revenue Growth
10.53
10.33
52 Week Low
$311.59
$362.50
52 Week High
$465.70
$519.68

Technical Indicators

Market Signals
Indicator
ADBE
VRTX
Relative Strength Index (RSI) 40.22 53.64
Support Level $350.58 $445.41
Resistance Level $356.68 $464.44
Average True Range (ATR) 8.04 6.74
MACD -1.59 -1.19
Stochastic Oscillator 8.37 39.12

Price Performance

Historical Comparison
ADBE
VRTX

About ADBE Adobe Inc.

Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: